ADC TherapeuticsADCT
Recorded

ADC Therapeutics 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration12 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Michael SchmidtSenior Biotech Analyst

Are we good? All right, welcome to this fireside chat with ADC Therapeutics. It is my great pleasure to welcome Ameet Mallik, CEO. Ameet, welcome. Thanks for joining us.

Ameet MallikCEO

Yeah, thank you, Michael. Appreciate it.

Michael SchmidtSenior Biotech Analyst

So we will do the lightning round version here. This has been a year of contrast, I guess, for ADC Therapeutics. You had the LOTIS-5 readout, FDA feedback, and now you have a very impressive LOTIS-7 data coming up at ASH. Maybe talk about how you think ADC Therapeutics is positioned as we enter 2027.

Ameet MallikCEO

Yeah, first of all, we have a commercial product. As a monotherapy, ZYNLONTA plays a meaningful role in the third-line plus DLBCL setting. As you mentioned, we have two really good data sets right now. We have the LOTIS-7 data looking at the combination of ZYNLONTA plus glofitamab in the second-line plus DLBCL setting. We also have ZYNLONTA monotherapy in marginal zone lymphoma. We think both of these data sets could be practice-changing, and we are pursuing a regulatory and compendia pathway for both of these. Given the recent PIPE and financial restructuring that we announced, we think we are in a very strong position to execute the strategy, and we think we have a good plan going forward.

Michael SchmidtSenior Biotech Analyst

Okay. Why don't we start talking about maybe starting with the near-term updates coming up at ASH. You obviously have, I think it's five orals in total, including the final LOTIS-7 data. Yeah, maybe talk about how important that LOTIS-7 data is and what will the ASH presentation essentially tell us beyond what we've seen in the abstract?

Ameet MallikCEO

Yeah, so you probably saw the abstract data, obviously, and so we're very impressed that in the 97 efficacy-evaluable patients looking at ZYNLONTA plus glofitamab in second-line plus DLBCL, we showed an 89% overall response rate and 75% complete response rate. Importantly, the duration of those responses was also good. The duration of CR at one year was 79%. Just by way of comparison, when you look at other bispecific combos, the CR rates are typically between 51% and 61%. The duration of CRs are typically at one year between 63% and 75%. So we think this data looks really good right now. So that's obviously one of the key presentations. We plan to have an enhanced data presentation at the presentation at ASH, including potentially updated data as well.

Michael SchmidtSenior Biotech Analyst

Okay. Then, yeah, how do you think about the development opportunity for LOTIS-7 longer term? So, how does this combination fit into the DLBCL landscape right now, and then how could you pursue that formally, I suppose?

Ameet MallikCEO

Yeah, so I think there's a lot of unmet need in the second-line plus setting. So outside of CAR-T, which is a clear standard of care, only about 20% of patients are getting a CAR-T in that second-line plus setting. Outside of that, the only targeted regimen that's approved today in second line is loncastuximab and lenalidomide. So there's very few options for patients right now in that second-line setting. Obviously, there could be some more approvals that come about, but nonetheless, if you don't get a CAR-T, there's really not a lot of great therapeutic options. We think the glofitamab plus ZYNLONTA combination can play a meaningful role in that second-line plus setting.

Ameet MallikCEO

We have a Type B meeting planned with the FDA this quarter to talk about the phase III design, looking at ZYNLONTA plus glofitamab versus what we want to have as a much more active comparator arm, and a lot of the details we will disclose once we have had that meeting with the FDA.

Michael SchmidtSenior Biotech Analyst

Okay. The data looks particularly strong in primary refractory patients and also in the post-CAR-T setting. In addition to the broad second-line registration study, which you might be planning, are there other opportunities, if we think about some of these subgroups, where the combination could be particularly useful, perhaps, again, there is an accelerated path to market potentially in those?

Ameet MallikCEO

Yeah, so I think, to your point, we are seeing a great response overall with a 75% complete response rate. Relapsed patients are close to 90%, and we are seeing more than a 60% complete response rate in both the primary refractory and the post-CAR-T population. Those are two of the highest unmet need populations that there are. So we are excited that in these very tough-to-treat populations, that we are seeing such compelling data. I think it is an area physicians are really excited about because there is not a lot of good options that work in those settings. Our plan right now from a regulatory standpoint is to go for a broad second-line plus population, but we will look at different options potentially for accelerated approval as well.

Michael SchmidtSenior Biotech Analyst

Okay, great. How does the safety profile compare to other therapies in this space?

Ameet MallikCEO

Overall, we think it looks good. I mean, the AEs that we see, the AE profiles, really consistent with the known profiles of both agents, glofitamab and ZYNLONTA. What we're seeing right now from a CRS and ICANS standpoint looks quite good. We had just over a 30% CRS rate, low grades of ICANS, and everything we saw was grade 1 or 2, with the exception of one case of grade 3 CRS. We think the fact that we're dosing ZYNLONTA ahead of the step-up dosing of glofitamab is helping to de-bulk the tumor and really reduce the rates and grades of CRS and ICANS, and we're seeing that play out now in about 100 patients. If you look at the grade 5 TEAEs, it's about 3%. Again, by way of comparison, when you look at just bispecific combo trials overall, that range is typically between 5% and 13%.

Ameet MallikCEO

We feel we're in a good place there. We think that the fact that we have infection prophylaxis in the protocol helps to really manage a lot of those AEs.

Michael SchmidtSenior Biotech Analyst

Right. Compendia listing was always one part of your plan and inclusion in NCCN guidelines. How quickly could the data be published and then be included in guidelines?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day